Parabilis Medicines(PBLS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PBLS Parabilis Medicines

盘前交易 07-07 07:55:21 EDT

29.20

-0.38

-1.28%

最高30.00	最低28.15	成交量28.17万
今开29.58	昨收29.58	日振幅6.25%
总市值34.50亿	流通市值9.78亿	总股本1.18亿
成交额827.27万	换手率0.84%	流通股本3,350万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PBLS","market":"US","secType":"STK","nameCN":"Parabilis Medicines","latestPrice":29.2,"timestamp":1783368000000,"preClose":29.58,"halted":0,"volume":281662,"delay":0,"changeRate":-0.0128465179175118,"floatShares":33500000,"shares":118145780,"eps":-67.08582,"marketStatus":"盘前交易","change":-0.38,"latestTime":"07-07 07:55:21 EDT","open":29.58,"high":30,"low":28.15,"amount":8272661.929208,"amplitude":0.062542,"askPrice":30.4,"askSize":5,"bidPrice":29,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-67.08582,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783431000000},"marketStatusCode":1,"adr":0,"listingDate":1781064000000,"exchange":"NASDAQ","adjPreClose":29.2,"postHourTrading":{"tag":"盘后","latestPrice":29.1595,"preClose":29.2,"latestTime":"19:52 EDT","volume":10298,"amount":304663.322,"timestamp":1783381972723,"change":-0.0405,"changeRate":-0.001387,"amplitude":0.018277},"volumeRatio":0.5383780828964841},"requestUrl":"/m/hq/s/PBLS","defaultTab":"news","newsList":[{"id":"1146739009","title":"美国银行全球研究首次覆盖Parabilis Medicines，给予买入评级及45美元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1146739009","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146739009?lang=zh_cn&edition=full","pubTime":"2026-07-06 19:39","pubTimestamp":1783337956,"startTime":"0","endTime":"0","summary":"美国银行全球研究已开始对生物制药公司Parabilis Medicines进行覆盖分析，并首次给予其股票“买入”评级。该机构为Parabilis Medicines设定了45.00美元的目标股价，显示出对其未来增长潜力的积极预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBLS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189403882","title":"Parabilis Medicines宣布完成规模扩大的首次公开募股，承销商全额行使超额配售权","url":"https://stock-news.laohu8.com/highlight/detail?id=1189403882","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189403882?lang=zh_cn&edition=full","pubTime":"2026-06-12 04:06","pubTimestamp":1781208398,"startTime":"0","endTime":"0","summary":"Parabilis Medicines宣布，其规模扩大的首次公开募股（IPO）已正式完成。此次发行中，承销商全额行使了购买额外股份的选择权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120727250","title":"异动解读｜Parabilis Medicines盘中上涨49.15%，IPO首日获10倍超额认购大幅高开","url":"https://stock-news.laohu8.com/highlight/detail?id=1120727250","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120727250?lang=zh_cn&edition=full","pubTime":"2026-06-11 02:03","pubTimestamp":1781114598,"startTime":"0","endTime":"0","summary":"6月10日，Parabilis Medicines盘中上涨49.15%，报29.83美元/股，成交额1.01亿美元。消息面上，公司当日完成美股IPO并挂牌上市，发行价定为每股20美元，高于此前17-19美元的推介区间，IPO认购需求达可供股份数的约10倍。本次IPO发行3350万股，募资约6.70亿美元；同时再生元制药以每股18美元认购约7500万美元股份，合计筹资近7.45亿美元。Parabilis Medicines是一家临床阶段生物制药公司，专注于开发用于癌症治疗的工程化肽疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104824154","title":"异动解读 | 美股IPO上市受热捧，Parabilis Medicines盘中大涨66.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=1104824154","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104824154?lang=zh_cn&edition=full","pubTime":"2026-06-11 01:12","pubTimestamp":1781111553,"startTime":"0","endTime":"0","summary":"生物科技公司Parabilis Medicines  今日盘中股价大幅飙升66.75%，成为市场焦点。Parabilis Medicines成立于2015年，专注于开发针对多种癌症及罕见肿瘤的治疗方案，此次IPO募集资金将主要用于推进其最领先的候选药物zolucatetide进入更后期的临床试验阶段，这增强了投资者对公司未来发展的信心。市场分析认为，尽管公司目前处于亏损状态，但其在癌症治疗领域的专业性和IPO带来的资金注入，为其后续的研发和商业化提供了关键支持，从而推动了股价的积极表现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642478833","title":"美股异动 | Parabilis Medicines(PBLS.US)登陆美股市场 开盘后股价涨超44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642478833","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642478833?lang=zh_cn&edition=full","pubTime":"2026-06-11 00:00","pubTimestamp":1781107200,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周三，聚焦癌症治疗的美国生物科技公司Parabilis Medicines(PBLS.US)登陆美股市场，开盘股价走高，截至发稿，该股涨44.35%，报28.87美元。IPO价格为20美元。Parabilis成立于2015年，专注于开发用于多种癌症及罕见肿瘤的治疗方案。公司拟将IPO募集资金用于推进其最领先候选药物zolucatetide进入更后期临床试验阶段。截至2025财年年末，Parabilis净亏损1.459亿美元，期末现金及现金等价物2,770万美元;前一财年净亏损为1.179亿美元，现金为4,730万美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"美股异动 | Parabilis Medicines(PBLS.US)登陆美股市场 开盘后股价涨超44%","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642414058","title":"癌症肽疗法新星Parabilis(PBLS.US)超区间定价IPO，获10倍超额认购 最终募资7.45亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2642414058","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642414058?lang=zh_cn&edition=full","pubTime":"2026-06-10 11:30","pubTimestamp":1781062200,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，聚焦癌症治疗的美国生物科技公司Parabilis Medicines完成了一项规模上调的美股IPO，发行价定在推介区间之上，叠加同步进行的私募配售，合计筹资近 7.45亿美元。在本次周二上调规模前，IPO认购需求已达可供股份数的约10倍。文件显示，截至 2025财年年末，Parabilis 净亏损 1.459亿美元，期末现金及现金等价物 2,770万美元;前一财年净亏损为 1.179亿美元，现金为 4,730万美元。Parabilis 成立于 2015年，专注于开发用于多种癌症及罕见肿瘤的治疗方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","PBLS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.parabilismed.com","stockEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":0.46},{"period":"ytd","weight":0.46}],"compareEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":0.0186},{"period":"3month","weight":0.1396},{"period":"6month","weight":0.0895},{"period":"1year","weight":0.2014},{"period":"ytd","weight":0.1017}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Parabilis Medicines, Inc.于2015年7月10日在特拉华州注册成立。该公司是一家临床阶段的生物制药公司，旨在开发变革性药物，解决历史上驱动人类疾病的不可药物蛋白靶点。其专有平台开创了Helicons，稳定的螺旋肽被设计用于细胞渗透，能够以高特异性结合扁平的细胞内蛋白质目标表面。","exchange":"NASDAQ","name":"Parabilis Medicines","nameEN":"Parabilis Medicines"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Parabilis Medicines(PBLS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Parabilis Medicines(PBLS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Parabilis Medicines,PBLS,Parabilis Medicines股票,Parabilis Medicines股票老虎,Parabilis Medicines股票老虎国际,Parabilis Medicines行情,Parabilis Medicines股票行情,Parabilis Medicines股价,Parabilis Medicines股市,Parabilis Medicines股票价格,Parabilis Medicines股票交易,Parabilis Medicines股票购买,Parabilis Medicines股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Parabilis Medicines(PBLS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Parabilis Medicines(PBLS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}